NeuroOrigin Brain Science Secures Tens of Millions in Pre-A Funding to Accelerate Commercialization of Cerebral Monitoring and Neuromodulation Products

VCBeat has learned that Sichuan Neurogin Biotechnology Electronic Co., Ltd. (hereinafter referred to as “Neurogin Brain Science”) has announced the completion of its Pre-A financing round, raising tens of millions of yuan. The round was led by Green Pine Medical & Health Fund. The funds raised will be primarily used for the research and development, as well as market promotion, of Neurogin Brain Science’s perioperative brain function monitoring products and next-generation neuromodulation devices.

Founded in 2014, Neurogin is a high-tech enterprise rooted in the fields of brain science, clinical medicine, and artificial intelligence, integrating the research and development and production of medical devices. The company is dedicated to applying cutting-edge technologies to brain science research and clinical diagnostics, providing advanced research equipment for biological and medical research institutions, as well as reliable diagnostic and therapeutic tools for clinical and health management organizations.

The brain science sector in which Neurogin operates is the most cutting-edge and frontier domain of life sciences, and also one of the most challenging “scientific fortresses” for humanity to conquer.

To delve deeper into the mysteries of the brain,Neurogin has assembled a core team led by internationally renowned scientists, spanning multiple disciplines including neuroscience, clinical medicine, multiphysics sensing, and biomedical engineering., such as a Professor in the Department of Psychology at the University of Texas (UT), a Chair Professor in the Department of Electrical and Computer Engineering at Southern Methodist University (SMU), a Chief Physician and Discipline Leader in Anesthesiology at West China Hospital of Sichuan University, and a Professor at the Institute of Thin Film Sensors and Intelligent Systems at Huazhong University of Science and Technology.

Furthermore, the management team of Neurogin Brain Science comprises professional executives from leading domestic and international enterprises and listed companies, bringing extensive experience in corporate management, investment and financing, technological R&D, and marketing. The company’s R&D team consists of PhDs and master’s degree holders from renowned universities, research institutions, and industry-leading enterprises both in China and abroad, possessing substantial expertise in the design, development, and testing of medical devices.

Leveraging its team’s strengths, Neurogin is grounded in cutting-edge brain science technologies and industry insights. It has amassed extensive experience in neuromodulation and physiological monitoring technologies and their clinical translation, employing advanced engineering methods to develop a comprehensive product portfolio covering both animal and human electroencephalography (EEG).

Addressing urgent unmet clinical needs, Neurogin Brain Science is precisely positioned at the intersection of brain science, clinical medicine, and artificial intelligence. The company has achieved key breakthroughs in autonomous system design, energy harvesting and conversion technologies, EEG acquisition techniques, and neural signal encoding/decoding, establishing a technologically competitive platform with international stature.

First, the SR1 EEG acquisition system is a medical-grade, compact, high-precision, and interference-resistant device for human electroencephalogram (EEG) signal acquisition. Its core performance matches that of mainstream products from leading industry manufacturers, thereby ensuring the data quality required for scientific research.Furthermore, the product boasts broad system compatibility, meeting the requirements of multidisciplinary research applications, including clinical studies. It is reported that the SR1 EEG Acquisition System obtained its Class II medical device registration certificate and was launched for commercial sale in September 2023.

SR1 EEG Acquisition Device

Secondly, Neurogin’s self-developed implantable animal EEG acquisition device, ImplatIQ, can be used for collecting cortical EEG signals from rats, mice, and primates in laboratory settings.The product consists of wireless acquisition devices, signal receiving terminals, and matching invasive electrodes, supporting simultaneous EEG acquisition and data retrieval for up to six animals. Furthermore, ImplatIQ supports multiple modulation modes, with a battery-inclusive system weighing less than 10 g, thereby meeting the requirements of behavioral studies.

ImplatIQ Implantable Animal EEG Acquisition Device

Finally, Neurogin has developed a neural data analysis platform that serves as an efficiency engine to help researchers scale up their outputs in brain science research.On the one hand, the code-free, independent analysis capabilities of automated neural data analysis platforms provide efficiency support for scaling up brain science research outcomes; on the other hand, the company’s professional algorithm team offers personalized data analysis services, leveraging advanced tools such as machine learning and artificial intelligence modeling to drive innovative development in brain science.

Neural Data Analysis Platform

These solutions and services demonstrate Neurogin’s innovation capabilities, technical prowess, and exceptional clinical translation capacity. These products are poised to drive revolutionary innovations and advancements in the brain science industry in the future.

Meanwhile, to address the critical demands in the field of brain science, Neurogin is actively fostering communication and collaboration with leading domestic research institutions and numerous Grade A tertiary hospitals across China. By promoting the close integration and translation of industry, academia, and research within the brain science sector, the company is laying a solid foundation for its comprehensive strategic layout and sustained innovation.

Addressing the perioperative brain function monitoring market with continuously growing demand,The company is engaging in in-depth collaboration with the Anesthesia and Surgery Center of West China Hospital, Sichuan University, based on the SR1 EEG acquisition system., to develop clinical research and products in the field of perioperative brain function monitoring, facilitating the realization of precision anesthesia. It is reported that the collaboration aims to commercialize the product by the end of 2024.

Neurogin has also accumulated thousands of hours of intraoperative multimodal brain function data through in-depth clinical practice. Leveraging this data, the company has successfully developed its proprietary large model for brain function monitoring. Looking ahead, Neurogin plans to continuously enhance the practicality and accuracy of its EEG analysis platform by utilizing extensive, high-quality clinical data.

It is worth mentioning that,Neurogin is also committed to developing a new generation of implantable neuromodulation products., leveraging globally leading transcutaneous power transfer technology and biocompatible materials with safety precision down to the micron level, to achieve miniaturization of neuromodulation systems. The company maintains comprehensive advantages across all stages, from basic materials to core components, with product performance reaching internationally advanced standards.

For this round of financing,Peng Jian, Chairman of Neurogin Brain ScienceStatement: We extend our deepest gratitude to Green Pine Capital for its support. I am truly grateful for the successful completion of this financing round. This achievement is not only the result of our team’s diligent efforts but also a testament to the trust investors have placed in us. The brain is the most vital and structurally complex organ in the human body. Globally, the field of brain science has entered an unprecedented period of rapid development, yielding disruptive theories and revolutionary technological breakthroughs. Over the past decade, we have consolidated our expertise and assembled a team of outstanding scientists with an international perspective, spanning foundational electrophysiological theory, clinical practice, advanced materials, and intelligent systems. Together, we have built an innovative and down-to-earth entrepreneurial team that has accumulated substantial scientific insights and R&D experience by addressing market and clinical needs. Moving forward, we will proceed with greater determination to enrich our product development pipeline, expand our market presence, and enhance our services. We are committed to repaying this trust through concrete actions, delivering superior products and solutions to more medical and research institutions.

Luo Fei, Founding Partner of Green Pine CapitalIt was stated that the aging trend in China is becoming increasingly pronounced, and understanding the structure and function of the brain is currently one of the most challenging frontier scientific issues. Therefore, we have long focused on the development prospects of neuroscience. Neurogin has established a series of products in the fields of perioperative precision brain function monitoring and neuromodulation by organically integrating and accumulating profound expertise in three aspects: theoretical support for brain function, engineering implementation, and clinical needs. Meanwhile, close collaboration with West China Anesthesia, which ranks first in the anesthesiology specialty, has laid a solid foundation for the industry-academia-research translation of EEG data acquisition. Neurogin is poised to contribute to the “Chengdu Opportunity” in the brain science industry.

Green Pine Capital was established in 2007 (its initiator, Green Pine Venture Capital, founded in 1996, is one of the earliest private venture capital firms in Shenzhen). Co-founded by venture capitalists Mr. Li Wei and Mr. Luo Fei, the firm has operated steadily through multiple economic cycles, with its core team possessing over 20 years of experience in equity investment. Green Pine Capital focuses on early-stage and growth-stage investments, prioritizing three hard-tech sectors: digital technology, precision medicine, and innovative materials. To date, its assets under management exceed RMB 18 billion, with over 400 invested projects, facilitating more than 70 portfolio companies in achieving successful M&A transactions or IPOs. Notable portfolio companies include SenseTime (00020.HK), BGI Genomics (300676), Kintor Pharmaceutical (09939.HK), Dynanonic (300769), MGI Tech (688114), and Orbbec (688322).